B
Bull
Bull · 25%VERV
$13.80
Scenario price
$11.130
+0.030 (+0.27%)At close
Loading chart…
- High
- 11.250
- Open
- 11.140
- VWAP
- 11.16
- Vol
- 10.31M
- Mkt Cap
- 399.68M
- Low
- 11.100
- Amount
- 115.02M
- EV/EBITDA, TTM
- -0.21
Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
Valuation Metrics
The current forward P/E ratio for Verve Therapeutics Inc (VERV) is -2.17, compared to its 5-year average forward P/E of -6.34.
Alphio AI Price Scenarios for VERV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.507-25NewsfilterLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
8.507-24PRnewswireLilly and Verve announce expiration of Verve tender offer
8.007-23NASDAQ.COMNoteworthy Wednesday Option Activity: WEN, HAS, VERV
- 4.507-23NASDAQ.COM
After Hours Most Active for Jul 23, 2025 : TSLL, INTC, KVUE, VERV, GOOGL, GOOG, NVDA, PATH, CMG, RKT, KMI, QS
7.006-27PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, CTLP, SAGE on Behalf of Shareholders
VERV FAQ — answered by Alphio AI
Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.